Steve Arkinstall

Steve obtained his D.Phil. from the University of Oxford, UK, and has 30 years of experience in bio-pharmaceutical drug discovery research across a range of disease areas and technology platforms. Previously, he worked at the prestigious Glaxo Institute for Molecular Biology in Geneva, Switzerland, where he studied novel disease mechanisms in several therapeutic indications including cancer and inflammatory diseases. Steve went on to serve as the President of the Serono Research Institute in Boston with a focus on oncology drug discovery delivering a number of molecules for clinical development.

After Serono was acquired by Merck KGaA, Steve took on several leadership roles including antibody discovery and protein engineering. More recently, he served as the Chief Scientific Officer at Kymab, a British therapeutic antibody discovery company, and Chief Executive Officer of Elstar Therapeutics focused on multi-functional protein immunotherapies and based in Cambridge MA. Now, as the CEO of Revitope Oncology, and as a cancer survivor himself, Steve’s passion is to build a strong pipeline of novel immunotherapies to treat patients suffering from life-threatening cancers unaddressed by existing treatments.